Refractory anemia with excess of blasts, unspecified
ICD-10 D46.20 is a billable code used to indicate a diagnosis of refractory anemia with excess of blasts, unspecified.
Refractory anemia with excess of blasts, unspecified (D46.20) is a hematological condition characterized by ineffective hematopoiesis leading to anemia, accompanied by an increased number of myeloid blasts in the bone marrow. This condition is classified under neoplasms of uncertain behavior, indicating that while it is not classified as a malignant neoplasm, it has the potential for progression to acute myeloid leukemia (AML). Patients typically present with symptoms of anemia such as fatigue, pallor, and weakness, and may also exhibit signs of leukopenia or thrombocytopenia. Diagnosis is confirmed through bone marrow biopsy, which reveals hypercellularity with a significant proportion of myeloid blasts. The management of refractory anemia with excess of blasts often involves supportive care, including blood transfusions and growth factor therapy, and may require more aggressive treatment such as chemotherapy or stem cell transplantation if progression to AML occurs. Regular monitoring and surveillance are crucial due to the risk of transformation into a more aggressive disease.
Detailed blood work results, bone marrow biopsy reports, and treatment plans.
Diagnosis and management of patients with unexplained anemia and elevated blast counts.
Ensure accurate recording of blast percentages and any transformation to acute leukemia.
Comprehensive treatment history, including chemotherapy regimens and response assessments.
Management of patients transitioning from refractory anemia to acute myeloid leukemia.
Monitor for signs of disease progression and document any changes in treatment strategy.
Used to monitor blood counts in patients with D46.20.
Document the reason for the CBC and any abnormal findings.
Hematologists should ensure that CBC results are correlated with clinical findings.
The term 'refractory' indicates that the anemia is resistant to standard treatments, necessitating careful monitoring and potential alternative therapies.
